Immune checkpoint inhibitors: a promising anticancer therapy

Sima Singh, Daniel Hassan, Hibah M. Aldawsari, Nagashekhara Molugulu, Rahul Shukla, Prashant Kesharwani

Research output: Contribution to journalReview ArticleResearchpeer-review

36 Citations (Scopus)


Immune checkpoint inhibitors (ICIs) are revolutionizing the treatment of many cancers and have demonstrated their potential as ‘cancer terminators’. However, ICI treatment also has constraints, such as its immune-related adverse events (irAEs) and therapeutic resistance. These drawbacks are gradually being overcome through better knowledge of the immune system, history of disease, duration of treatment, combinational drug regimes, adequate biomarkers, and effective patient response monitoring. In this review, we discuss the present ICI therapy landscape and its therapeutic outcomes for various diseases. We also highlight biomarkers related to the ICI response.

Original languageEnglish
Pages (from-to)223-229
Number of pages7
JournalDrug Discovery Today
Issue number1
Publication statusPublished - Jan 2020

Cite this